SCHEMBL3961547

SCHEMBL3961547

Cc1cnc(Cl)nc1-c1cc2ccc(C(=O)N3CCOCC3)cc2s1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.51
EIF4E P06730 1/20 0.45
MKNK1 Q9BUB5 1/20 0.45
MKNK2 Q9HBH9 1/20 0.45
LRRK2 Q5S007 5/20 0.45
PKM P14618 1/20 0.45
TSHR P16473 1/20 0.43
HTT P42858 1/20 0.43
GAA P10253 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
PHGDH O43175 1/20 0.42
PDE4B Q07343 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
RAB9A P51151 1/20 0.41
ABL1 P00519 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3965558 0.90 PKM (0.49) HPGDEIF4EMKNK1MKNK2LRRK2
SCHEMBL3970210 0.81 NPC1 (0.41) KDM4ESMN1; SMN2RAB9A
SCHEMBL3962466 0.78 HDAC1 (0.48) HPGDHTTGAAKDM4EALDH1A1
SCHEMBL3968816 0.78 HDAC6 (0.43) HPGDALDH1A1SMN1; SMN2RAB9A
Hydrochloric Acid SCHEMBL3971783 0.78 TYRO3 (0.40) EIF4EMKNK1MKNK2LRRK2KDM4E
Hydrochloric Acid SCHEMBL3965791 0.77 DYRK2 (0.43) EIF4EMKNK1MKNK2LRRK2KDM4E
SCHEMBL3964511 0.77 LRRK2 (0.46) EIF4EMKNK1MKNK2LRRK2ABL1
Hydrochloric Acid SCHEMBL3967145 0.77 LRRK2 (0.46) HPGDEIF4EMKNK1MKNK2LRRK2
Hydrochloric Acid SCHEMBL3970078 0.76 DYRK2 (0.41) EIF4EMKNK1MKNK2LRRK2KDM4E
Hydrochloric Acid SCHEMBL4084919 0.76 LRRK2 (0.42) HPGDLRRK2GAAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1989200-B1 [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES LILLY CO ELI (US) 2009-07-29 EP disclosed
US-7547691-B2 [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases ELI LILLY AND COMPANY (US) 2009-06-16 US disclosed
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases ELI LILLY AND COMPANY 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases NFKBIA, IKBKB, IKBKG HPGD 2287/4885EIF4E 949/4885MKNK1 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.